Estabalished
Credentials
Business area
Customers
Plutoheat is a tech-driven enterprise integrating R&D, regulatory registration, pharmaceutical trade and industrial investment. We focus on four core businesses: international pharmaceutical trading, technology transfer, regulatory affairs consulting, and supply chain & sales channel integration. With a unique business model, we layout blue ocean markets and help Chinese pharmaceutical products enter the global stage. Our products include:
As a key player in China's pharmaceutical formulation internationalization, Plutoheat upholds the philosophy of "Caring for Human Health". Leveraging GMP certifications from China, the EU, FDA, PMDA, TGA, and other authorities, plus an advanced quality management system, we deliver high-quality, safe, and effective generics and biopharmaceuticals (including plasma products, vaccines, and antibodies) to over 60 countries across five continents. Our professional registration team, armed with hundreds of CTD-format dossiers, accelerates product launch in target markets. We are also the first Chinese company to introduce Chinese generics to Brazil.
As a core business segment of Plutoheat, API and intermediate export offers end-to-end services covering production, registration, supply, and after-sales support. We specialize in generic R&D processes and market-specific registration requirements, providing efficient product matching and project support for new initiatives and alternative sourcing. Our core products span antibiotics, oncology, cardiovascular, central nervous system, anesthesia, immunosuppressants, and contract media, with exclusive regional partnerships and strategic collaborations with renowned pharmaceutical companies worldwide. We serve regions including South America, MENA, CIS countries, South Korea, Japan, and Southeast Asia.
Specializing in antibiotic APIs and intermediates, including tazobactam, sulbactam, meropenem side chains, and sultamicillin intermediates. Products are primarily exported to Europe, the Americas, and Southeast Asia. We integrate upstream and downstream processes to reduce costs and enhance competitiveness, offering a complete industrial chain from tazobactam intermediates to sterile piperacillin/tazobactam powder. Our facilities meet EU, US, Japanese, and Chinese GMP standards, with DMF filings completed and global registrations launched in 2025 to expand market share.
Plutoheat provides diversified high-quality cosmetics raw material solutions, including Green Surfactants, Thickeners & Stabilizers, Moisturizers, Anti-inflammatory & Spot-Removing Agents, Make-Up Products, and Antibacterial Agents. Our products empower cosmetics innovation with safe, effective, and reliable core ingredients.
Plutoheat has established long-term strategic partnerships with internationally renowned pharmaceutical leaders and domestic listed pharmaceutical companies, covering therapeutic areas such as cardiovascular, central nervous system, anti-tumor, and respiratory. We focus on China's pharmaceutical market dynamics, supplying high-quality imported APIs with concurrent US and EU registrations—supporting domestic partners in securing first generic approvals, seizing market opportunities, and enhancing competitiveness in both domestic and global formulation registrations. Our services have earned wide recognition and praise in the industry.
Plutoheat invites global partners for cross-border pharma R&D and overseas market expansion.
Plutoheat joined CPHI China (Shanghai), connected global pharma resources, showcased core products, and secured cooperation intentions.
Plutoheat’s Hangzhou mid-year meeting summarized H1 results, set H2’s "innovation + cost-saving" direction, and aligned team goals.
API Guangzhou concluded; Plutoheat engaged domestic/overseas buyers, demonstrating strength in pharmaceutical raw materials.
